Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408888 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01408888 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 29 participants.
The verdict
NCT01408888, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together. The duration of participation in this study is expected to be approximately 61 days. The study requires 2 clinic confinements (one of 2 nights and one of 19 nights duration). The study involves 3 injections, subcutaneous, of 1.5 milligrams (mg) LY2189265 and 18 daily doses of 100 mg sitagliptin tablets administered orally.
Interventions
- DRUG Sitagliptin
- BIOLOGICAL LY2189265
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01408888
The ClinicalTrials.gov registry entry for NCT01408888 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sitagliptin is the first listed.
NCT01408888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01408888 about?
NCT01408888 is a clinical study titled "A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes". The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together. The duration of participation in this study is expected to be approximately 61...
What is the current status of trial NCT01408888?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2011-08. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01408888?
The interventions under investigation include: Sitagliptin (DRUG), LY2189265 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01408888?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.